Problems with Alpharadin ASCO SRE data?
At the 2012 American Society of Clinical Oncology (ASCO) annual meeting, data was presented by Dr Oliver Sartor (ASCO 2012 Abstract 4551) that showed radium-223 (Alpharadin) significantly delayed time to first skeletal-related event (SRE) in patients with castratation-resistant prostate cancer (CRPC) and bone metastases.
The SRE data for radium-223 from the ALSYMPCA phase III trial was first presented at ASCO GU earlier this year.
ASCO 2012 radium-223 data discrepancies
Algeta in a communication I received today, however, have advised that the data contained in the ASCO 2012 abstracts has “discrepancies.” In the absence of more precise information, the discrepancies may or may not be significant.
There is “No data,” Sartor told the ASCO 2012 audience. As a result he recommended the use of less toxic therapies first and that patients be involved in the decision making. Not quite the guidance the audience perhaps hoped for.